Exploring Ultrasound-Guided High-Intensity Focused Ultrasound for Safe Placental Vessel Occlusion in Early-Onset Twin-Twin Transfusion Syndrome
Posted innews OB/GYN & Women's Health

Exploring Ultrasound-Guided High-Intensity Focused Ultrasound for Safe Placental Vessel Occlusion in Early-Onset Twin-Twin Transfusion Syndrome

This article reviews a Phase 1 clinical trial demonstrating the technical feasibility and short-term safety of ultrasound-guided high-intensity focused ultrasound for placental vessel occlusion in early-onset twin-twin transfusion syndrome, highlighting potential benefits and current limitations.
Evaluating Pembrolizumab, Bevacizumab, and Oral Metronomic Cyclophosphamide in Heavily Pretreated Platinum-Resistant Ovarian Cancer: Real-World Outcomes and Clinical Implications
Posted innews OB/GYN & Women's Health Oncology

Evaluating Pembrolizumab, Bevacizumab, and Oral Metronomic Cyclophosphamide in Heavily Pretreated Platinum-Resistant Ovarian Cancer: Real-World Outcomes and Clinical Implications

This study assesses the efficacy and safety of pembrolizumab combined with bevacizumab and oral metronomic cyclophosphamide in heavily pretreated platinum-resistant ovarian cancer patients, showing modest disease control with manageable toxicity in a real-world setting.
Genetic Testing in Endometrial Cancer: Prevalence of Pathogenic Germline Variants and Implications for Clinical Practice in a Diverse Community Cohort
Posted innews OB/GYN & Women's Health Oncology

Genetic Testing in Endometrial Cancer: Prevalence of Pathogenic Germline Variants and Implications for Clinical Practice in a Diverse Community Cohort

In a large, diverse cohort of women with endometrial cancer, 11.9% harbored pathogenic germline variants, including Lynch syndrome and homologous recombination deficiency-related mutations. Testing at diagnosis identified most Lynch syndrome cases, highlighting the need for expanded genetic screening strategies.
Evaluating the Safety of GLP-1 Receptor Agonists and New-Generation Glucose-Lowering Agents in Pregnant Women with Type 2 Diabetes: Insights from a French Nationwide Study
Posted inDiabetes & Endocrinology news OB/GYN & Women's Health

Evaluating the Safety of GLP-1 Receptor Agonists and New-Generation Glucose-Lowering Agents in Pregnant Women with Type 2 Diabetes: Insights from a French Nationwide Study

A French nationwide cohort study finds first-trimester exposure to second-line glucose-lowering agents, including GLP-1 receptor agonists, is generally safe for pregnancies with type 2 diabetes, though a slight increase in cardiac malformations cannot be excluded.